- Home
- TMP vs TSHA Comparison
TMP vs TSHA Comparison
Compare TMP & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TMP | TSHA |
|---|---|---|
| Founded | 1836 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TMP | TSHA |
|---|---|---|
| Price | $74.15 | $5.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $72.00 | $10.22 |
| AVG Volume (30 Days) | 53.7K | ★ 3.4M |
| Earning Date | 01-30-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 27.02 | N/A |
| EPS | ★ 5.90 | N/A |
| Revenue | ★ $316,920,000.00 | $6,310,000.00 |
| Revenue This Year | $16.28 | N/A |
| Revenue Next Year | $1.90 | N/A |
| P/E Ratio | $12.57 | ★ N/A |
| Revenue Growth | ★ 10.67 | N/A |
| 52 Week Low | $54.16 | $1.05 |
| 52 Week High | $78.30 | $5.95 |
Technical Indicators
Market Signals| Indicator | TMP | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 67.17 | 67.47 |
| Support Level | $69.00 | $5.22 |
| Resistance Level | $72.51 | $5.54 |
| Average True Range (ATR) | 2.16 | 0.32 |
| MACD | 0.51 | 0.15 |
| Stochastic Oscillator | 80.62 | 92.43 |
Price Performance
Historical ComparisonAbout TMP Tompkins Financial Corporation
Tompkins Financial Corp is a Financial Holding Company. It has three business segments, consisting of banking, insurance and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Insurance is comprised of property and casualty insurance services and employee benefit consulting. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates majority of its revenue from Banking segment.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.